Viva Biotech Holdings · HKEX:1873
Viva Biotech — H1 2025 Earnings Presentation
32 slides from Viva Biotech's earnings presentation, Aug 29, 2025
Slide 1: Viva Biotech 2025 Interim Results
Viva Biotech 2025 Interim Results 29 August 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain information set forth in this presentation contains “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our managemen
Slide 3: Contents
01 Business Highlights 02 Financial Performance CONTENTS 03 Future Strategies Q&A Session
Slide 4: Part 1: Business Highlights
Viva PART 1: Business Highlights
Slide 5: World Leading One-stop Innovative Original Drug R&D and Production Platform
World Leading One-stop Innovative Original Drug R&D and Production Platform CDMO Research and EFS Investment and CRO Business Production Business Incubation Business Focus on FIC's Discover business, take Provide innovative drug partners with small Focus on discovering and investing SBDD as the core
Slide 6: Equity Structure of Viva Biotech
Equity Structure of Viva Biotech Viva Biotech Holdings (1873.HK) 10.87% Strategic investors 26.34% 72.9% 100% 100% Small Molecule Incubator CRO CDMO 100% 100% 100% Onshore Offshore Shanghai Jiaxing Suzhou Chengdu Overseas Shanghai Ningbo Taizhou Equity Incubators Equity Holding Holding Platform Plat
Slide 7: Integrated Platform for Comprehensive Original Drug R&D and Manufacturing Services
Integrated Platform for Comprehensive Original Drug R&D and Manufacturing Services one-stop R&D service platform for innovative novel drugs Affinity-Based Drug Screening Mass Spectrometry (ASMS, INTACT-MS) SPR Drug Metabolism Crystal Soaking (ADME/DMPK) Protein Science and V-DEL Structural Research
Slide 8: Business Highlights Overview
Overview Business Highlights RMB Million Revenue in 2025H1 reached RMB 831.9 million, gross profit reached RMB 2500 45.0% 339.4 million 40.8% 1986.7 2000 40.0% Gross profit margin 40.8%, +6.3pp YOY 34.5% Adjusted net profit reached RMB 183.5 million, +9.1% YOY 34.6% 1500 35.0% Adjusted Earni
Slide 9: CRO Business: CRO Revenue Returned to Positive Growth
Business Highlights CRO Business：CRO Revenue Returned to Positive Growth, with a Significant Recovery in Domestic Growth RMB Million Revenue: RMB 422.8 million, +9.6% YOY Adjusted gross profit: RMB 194.6 million, +16.4% YOY CFS SFE 5.9 Adjusted gross profit margin:46.0%, +2.7pp YOY 5.9 5.9 T
Slide 10: CRO Business: Operational Efficiency Continues to Improve and Customers Grow
CRO Business：Operational Efficiency Continues to Improve and the Number of Customers Grows Steadily CRO R&D Personnel Remain Stable and Served Top 50 Global Operational Efficiency Continues to Improve Pharmaceutical Companies 2025H1 1098 2024 1121 2024H1 1117 Based on Total Annual Revenue in 2025H1
Slide 11: CRO Business: Targets and Protein Structures Delivered
CRO Business：Solid Operations with Continued Increase in the Number of Targets and Protein Structures Delivered Radiation Source Stage Unit: hours Number of Target and Protein Structure Deliveries 2025H1 834 2024 1867 Independent Target Research: +89 YOY 2024H1 873 Accumulative Research: 2187
Slide 12: AI Technology Driven Experiments Pave the Way for a New Era in Drug Development
AI Technology Driven Experiments Pave the Way for a New Era in Drug Development Target Safety and Efficacy Hit Identification Lead Optimization Identification Evaluation Virtual Screening and ADME/PK AI Structure Prediction Free Energy Perturbation Molecular Generation Property Prediction Viva Struc
Slide 13: AI-driven Drug Design – a New Pharmaceutical Logic
AI-driven Drug Design – a New Pharmaceutical Logic 16-25 weeks 6-12 weeks 6-24 months 12-36 months Screening Validation Hit-to-Lead Lead Optimization Target • Protein production • Resynthesis and testing • Compound activity optimization • Molecule design Selection • HTS screening • Orthogonal assay
Slide 14: AI-Driven Drug Discovery—Three Core Functional Modules of the AIDD Platform
AI-Driven Drug Discovery—Three Core Functional Modules of the AIDD Platform • Biological Large Language Model(Bio-LLM) • Complex Structure Prediction • AI-Generated Small Molecule Drug Candidates • Antibody Engineering Platform • Active-learning Augmented Virtual • Peptide De Novo Design Screening(V
Slide 15: CDMO R&D and Production Services
Business Highlights CDMO R&D and Production Services RMB Million Revenue of Langhua: RMB 409.0 million, adjusted gross profit of Langhua: RMB 155.1 million 248.0 Adjusted gross profit margin of Langhua: 37.9%, +7.9pp YOY CDMO: Revenue RMB 248.0 million; adjusted gross profit margin 49.4%, +8.7
Slide 16: CDMO Business: New Commercialization Projects and Capacity Construction
CDMO Business: New Commercialization Projects Showed Promise and Capacity Construction Steadily Advance Revenue and Adjusted Gross Profit from CDMO RMB Million C 1 A1 248.0 B 1 122.5 2025H1 Revenue Adjusted Gross Profit Revenue from CDMO: RMB 248.0 million; The decrease in revenue was primarily at
Slide 17: CMC Business Optimization and Adjustment Basically Completed
The Optimization and Adjustment of CMC Business Have Been Basically Completed, the Profitability Has Improved Significantly Constant Increase in the Number of CMC Projects The Overall CMC R&D Staff Remain Stable Projects Persons 2025H1 279 2025H1 100 2024 255 2024 113 2024H1 218 2024H1 117 Internal
Slide 18: EFS Investment & Incubation Business
Business Highlights EFS Investment & Incubation Business RMB Million As the end of the reporting period，the Group has invested a total of 93 1469.8 1369.0 1409.0 portfolio companies. 1180.4 1190.6 During the reporting period，several portfolio companies achieved 1163.8 partially exits，which succe
Slide 19: VBI Investment Exits and Components Overview
VBI Investment Exits and Components Overview In 2025H1，VBI has invested in a total of 93 portfolio companies. The Group has successfully realized 18 investment exits or partial exits, and the enterprises invested in the incubation covered multiple indications, multiple molecular models and multipl
Slide 20: Continuous Expansion of Drug Pipeline, with Ongoing Financing Progress
Continuous Expansion of Drug Pipeline, with Ongoing Financing Progress • In July, 2025, VivaVision Biotech successfvully completed the D2+ round of financing delivery exceeding RMB100 million, which was mainly used to 228 Pipeline Projects in Portfolio Companies accelerate the clinical progress in t
Slide 21: Key Projects in VBI Investment Portfolio
Key Projects in VBI Investment Portfolio No. Name Country Mechanism Indication Pipeline Company Overview Cardiovascular A precision medicine company focused on discovering and developing innovative tissue and cell-selective genomic drugs, its unique focus is RNA- Disease, guided programmable therape
Slide 22: Part 2: Financial Performance
PART 2: Financial Performance
Slide 23: Financial Performance of the Group: Profitability Continues to Improve
Financial Performance of the Group: Profitability Continues to Improve Revenue of the Group RMB million Adjusted Gross Profit RMB million YOY Increased 1.0% 981.8 831.9 346.2 349.8 2024H1 2025H1 2024H1 2025H1 Adjusted Non-IFRS Net Profit Experienced a Significant YOY Increase Adjusted EBITDA Experie
Slide 24: CRO Financial Statistics
CRO Financial Statistics: Positive Growth in Both Revenue and Gross Profit, Significant Improvement in HR Efficiency CRO Revenue RMB million Adjusted Gross Profit RMB million YOY Increased 9.6% YOY Increased 16.4% 385.9 422.9 167.2 194.6 2024H1 2025H1 2024H1 2025H1 No. of CRO R&D personnel Persons A
Slide 25: CDMO Financial Statistics
CDMO Financial Statistics: Resulting From the Optimization and Adjustment of Business Structure, the Gross Profit Margin Has Significantly Increased Revenue and Adjusted Gross Profit of Langhua Gross Profit Margin Trend of Langhua RMB million 37.9% 595.9 30.0% 409.0 179.0 155.1 2024H1 2025H1 2024H1
Slide 26: Revenue Classifications of Principal Activities
Revenue Classifications of Principal Activities As at June 30, 2025 CDMO and commercialization Drug discovery services VBI Total service Types of goods or services RMB’000 RMB’000 RMB’000 RMB’000 Revenue from non-investees Full-time-equivalent (FTE) 315,071 - - 315,071 Fee-for-service (FFS) 87,999 1
Slide 27: Items Measured at Fair Value with Changes Recognized in Profit or Loss
Items Measured at Fair Value with Changes in Fair Value Recognized in Profit or Loss The movements in the carrying value of unlisted investments at FVTPL for the reporting period are as follows ： RMB’000 January 1, 2025 941,241 Acquired 9,713 Recognized from SFE revenue 535 Gain on fair value change
Slide 28: Appendix: Adjusted Non-IFRS Net Profit
APPENDIX: Adjusted Non-IFRS Net Profit 2025H1 2024FY 2024H1 2023FY 2023H1 2022FY RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Net Profit / (Loss) 148,637 221,987 144,237 -99,790 13,659 -504,220 Add: Fair Value Gain on Financial Liabilities at - -174,323 -10,050 FVTPL Add: interest expenses of the
Slide 29: Part 3: Future Strategies
Viva PART 3: Future Strategies
Slide 30: Improve Capacity Building for Front-end Projects, Expand Whole Industry Chain Service
Improve Capacity Building for Front-end Projects, Continue to Expand the Whole Industry Chain Service Downstream To Establish an Open and Cooperative Platform and a Win-win Ecosystem for Global Biopharmaceutical Innovators Early-stage preclinical service Raise technology barriers and expand servic
Slide 31: Q&A Session
Viva Q&A Session
Slide 32: Thanks
Thanks No.735, Ziping Road, Pudong New Area, Shanghai 201318, China —— Tel: +86 21 6089 3288 E-mail: info@vivabiotech.com www.vivabiotech.com
Viva Biotech Holdings — H1 2025 Earnings Presentation on 6ix